Literature DB >> 1318867

Synergistic uveitic effects of tumor necrosis factor-alpha and interleukin-1 beta.

L N Fleisher1, J B Ferrell, M C McGahan.   

Abstract

Tumor necrosis factor (TNF) and interleukin-1 (IL-1), cytokines with multiple, overlapping biologic activities, have been shown to interact synergistically in nonocular tissues. To test the hypothesis that coinjection of TNF and IL-1 interact synergistically in the eye, low, marginally inflammatory doses of human recombinant TNF-alpha (4000 U), IL-1 beta (40 U), and TNF-alpha+IL-1 beta (TNF-alpha/IL-1 beta) were injected into the vitreal chamber of the rabbit eye, and inflammation was assessed at 6, 24, 48, and 168 hr post-cytokine injection. TNF-alpha/IL-1 beta induced an anterior uveitis that was barely detectable at 6 hr, increased at 24 hr, peaked at 48 hr, and largely resolved by 168 hr. Synergy was observed for infiltration of inflammatory leukocytes into aqueous humor at 24 and 48 hr and for protein and prostaglandin E levels in aqueous humor at 48 hr. Based upon protein levels in vitreous humor, TNF-alpha/IL-1 beta also induced a posterior uveitis. This posterior uveitis was not apparent until 48 hr and then increased significantly at 168 hr. At 48 and 168 hr, the effects of TNF-alpha/IL-1 beta on protein levels in vitreous humor were consistent with a synergistic interaction. Results of separate experiments using higher dose combinations of TNF-alpha/IL-1 beta and a longer time course suggested that the effects of TNF-alpha/IL-1 beta on the blood vitreous barrier persisted beyond 168 hr. The results of this study support the hypothesis that TNF-alpha and IL-1 beta interact synergistically when injected into the rabbit eye.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318867

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

Review 1.  Macular oedema: the role of soluble mediators.

Authors:  D Kent; S A Vinores; P A Campochiaro
Journal:  Br J Ophthalmol       Date:  2000-05       Impact factor: 4.638

2.  How do you know?

Authors:  J T Rosenbaum; A Deodhar; E B Suhler; J R Smith
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

Review 3.  Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions.

Authors:  Michelle C Callegan; Michael Engelbert; David W Parke; Bradley D Jett; Michael S Gilmore
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

Review 4.  Biologic agents in experimental autoimmune uveitis.

Authors:  Gian Paolo Giuliari; Ama Sadaka; David M Hinkle
Journal:  Int Ophthalmol       Date:  2013-03-14       Impact factor: 2.031

5.  Mediators of the ocular inflammatory response to interleukin-1 beta plus tumor necrosis factor-alpha.

Authors:  L Fleisher; J Ferrell; C McGahan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-02       Impact factor: 3.117

6.  Synergistic effects of gamma interferon on inflammatory mediators that induce interleukin-6 gene expression and secretion by human retinal pigment epithelial cells.

Authors:  C N Nagineni; B Detrick; J J Hooks
Journal:  Clin Diagn Lab Immunol       Date:  1994-09

7.  Novel production of interleukin-1 receptor antagonist peptides in normal human cornea.

Authors:  M C Kennedy; J T Rosenbaum; J Brown; S R Planck; X Huang; C A Armstrong; J C Ansel
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

8.  Early administration of adalimumab for paediatric uveitis due to Behçet's disease.

Authors:  Tomona Hiyama; Yosuke Harada; Takehiko Doi; Yoshiaki Kiuchi
Journal:  Pediatr Rheumatol Online J       Date:  2019-06-10       Impact factor: 3.054

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.